Cam Gallagher net worth and biography

Cam Gallagher Biography and Net Worth

Cam Gallagher has been a member of the board of directors since our founding. Mr. Gallagher has more than 27 years of experience with a focus on corporate development, marketing and early stage company formation and financing. In addition to Zentalis, he currently serves on the board of directors of VelosBIO, Ocuphire and SelectION. He is currently Chief Business Officer of Immusoft, a private company developing gene modified cell therapies for orphan diseases. Previously, Cam was a board member and Chief Business Officer at Retrosense Therapeutics, which was acquired by Allergan in 2016. He was the Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Prior to these roles he held leadership positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Mr. Gallagher holds an MBA from the University of San Diego and a BS in Business Administration from Ohio University.

What is Cam Gallagher's net worth?

The estimated net worth of Cam Gallagher is at least $8.20 million as of January 17th, 2023. Mr. Gallagher owns 352,011 shares of Zentalis Pharmaceuticals stock worth more than $8,198,336 as of February 6th. This net worth estimate does not reflect any other assets that Mr. Gallagher may own. Additionally, Mr. Gallagher receives a salary of $515,180.00 as Director at Zentalis Pharmaceuticals. Learn More about Cam Gallagher's net worth.

How old is Cam Gallagher?

Mr. Gallagher is currently 53 years old. There are 5 older executives and no younger executives at Zentalis Pharmaceuticals. The oldest executive at Zentalis Pharmaceuticals is Dr. Mark Lackner Ph.D., Chief Translational Officer & Head of Biomarker Strategy, who is 56 years old. Learn More on Cam Gallagher's age.

What is Cam Gallagher's salary?

As the Director of Zentalis Pharmaceuticals, Inc., Mr. Gallagher earns $515,180.00 per year. There are 2 executives that earn more than Mr. Gallagher. The highest earning executive at Zentalis Pharmaceuticals is Dr. Kevin D. Bunker Ph.D., Co-Founder & Chief Scientific Officer, who commands a salary of $648,840.00 per year. Learn More on Cam Gallagher's salary.

How do I contact Cam Gallagher?

The corporate mailing address for Mr. Gallagher and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected] Learn More on Cam Gallagher's contact information.

Has Cam Gallagher been buying or selling shares of Zentalis Pharmaceuticals?

During the last ninety days, Cam Gallagher has sold $451,700.00 in Zentalis Pharmaceuticals stock. Most recently, Cam Gallagher sold 10,000 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $24.15, for a transaction totalling $241,500.00. Following the completion of the sale, the president now directly owns 352,011 shares of the company's stock, valued at $8,501,065.65. Learn More on Cam Gallagher's trading history.

Who are Zentalis Pharmaceuticals' active insiders?

Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Zentalis Pharmaceuticals?

In the last twelve months, insiders at the sold shares 28 times. They sold a total of 257,046 shares worth more than $9,798,239.64. The most recent insider tranaction occured on January, 17th when President Cam Gallagher sold 10,000 shares worth more than $241,500.00. Insiders at Zentalis Pharmaceuticals own 19.9% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.

Information on this page was last updated on 1/17/2023.

Cam Gallagher Insider Trading History at Zentalis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2023Sell10,000$24.15$241,500.00352,011View SEC Filing Icon  
1/5/2023Sell10,000$21.02$210,200.00362,011View SEC Filing Icon  
11/15/2022Sell12,500$22.77$284,625.00372,011View SEC Filing Icon  
11/7/2022Sell12,500$23.67$295,875.00396,885View SEC Filing Icon  
10/17/2022Sell12,500$23.51$293,875.00409,385View SEC Filing Icon  
10/5/2022Sell12,500$22.32$279,000.00431,885View SEC Filing Icon  
9/15/2022Sell12,500$25.26$315,750.00454,385View SEC Filing Icon  
4/5/2022Sell10,000$50.48$504,800.00355,813View SEC Filing Icon  
3/15/2022Sell10,000$41.92$419,200.00View SEC Filing Icon  
3/7/2022Sell10,000$44.94$449,400.00View SEC Filing Icon  
2/14/2022Sell7,188$50.19$360,765.72View SEC Filing Icon  
2/7/2022Sell10,000$53.45$534,500.00View SEC Filing Icon  
1/18/2022Sell10,000$62.64$626,400.00View SEC Filing Icon  
1/5/2022Sell10,000$75.49$754,900.00View SEC Filing Icon  
12/15/2021Sell10,000$74.03$740,300.00View SEC Filing Icon  
12/6/2021Sell10,000$71.33$713,300.00View SEC Filing Icon  
11/15/2021Sell10,000$75.36$753,600.00View SEC Filing Icon  
11/5/2021Sell10,000$82.95$829,500.00View SEC Filing Icon  
10/1/2021Sell10,000$66.15$661,500.00View SEC Filing Icon  
9/1/2021Sell10,000$67.52$675,200.00470,962View SEC Filing Icon  
8/2/2021Sell10,000$51.02$510,200.00483,419View SEC Filing Icon  
7/6/2021Sell15,798$46.88$740,610.24View SEC Filing Icon  
7/2/2021Sell10,000$49.58$495,800.00View SEC Filing Icon  
6/1/2021Sell10,000$54.06$540,600.00516,845View SEC Filing Icon  
5/3/2021Sell10,000$59.25$592,500.00534,373View SEC Filing Icon  
1/4/2021Sell10,000$51.93$519,300.00577,773View SEC Filing Icon  
12/7/2020Sell6,692$53.52$358,155.84613,471View SEC Filing Icon  
12/4/2020Sell7,474$50.98$381,024.52613,471View SEC Filing Icon  
11/23/2020Sell10,000$46.54$465,400.00View SEC Filing Icon  
See Full Table

Cam Gallagher Buying and Selling Activity at Zentalis Pharmaceuticals

This chart shows Cam Gallagher's buying and selling at Zentalis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals logo
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $22.05
Low: $21.76
High: $24.10

50 Day Range

MA: $21.17
Low: $18.07
High: $24.94

2 Week Range

Now: $22.05
Low: $17.33
High: $55.42


317,016 shs

Average Volume

575,567 shs

Market Capitalization

$1.26 billion

P/E Ratio


Dividend Yield